山东医药2024，Vol.64Issue(16)：1-5,5.DOI:10.3969/j.issn.1002-266X.2024.16.001
血清miR-22-3p、CYR61水平对乳腺癌诊断及复发转移预测的临床价值
Value of serum miR-22-3p and CYR61 levels in diagnosis of breast cancer and their prediction on recurrence and metastasis
摘要
Abstract
Objective To investigate the diagnostic value of serum microRNA-22-3p(miR-22-3p)and cysteine-rich protein 61(CYR61)levels in breast cancer and their prediction on recurrence and metastasis.Methods Totally 110 patients with breast cancer(observation group)receiving improved radical surgery were selected and followed up for 1 year;there were 25 patients with recurrence and metastasis and 85 patients without recurrence and metastasis.Mean-while,110 patients with benign breast diseases(control group)were selected during the same period.Peripheral venous blood of all subjects was collected and serum was retained by centrifugation.Serum miR-22-3p was detected by RT-qPCR and serum CYR61 was detected by ELISA.Serum miR-22-3p and CYR61 levels were compared between the observation group and the control group,and between patients with recurrence and metastasis and those without recurrence and metas-tasis.The value of serum miR-22-3p and CYR61 levels in diagnosis of breast cancer and their predictive value on recur-rence and metastasis were analyzed by receiver operating characteristic(ROC)curve.Pearson correlation analysis was used to analyze the relationship between serum miR-22-3p level and serum CYR61 level in breast cancer patients.Results The levels of miR-22-3p in the observation group and control group were 0.65±0.14 and 1.02±0.23,respec-tively,and the levels of CYR61 in the serum were(128.63±25.72)and(96.45±17.31)μg/L,respectively.The serum miR-22-3p level in the observation group was lower than that in the control group,and the serum CYR61 level was higher than that in the control group(t=14.802 and 10.886,respectively,both P<0.01).ROC curve analysis showed that the area under the curve(AUC)of serum miR-22-3p and CYR61 levels in the diagnosis of breast cancer alone and combined were 0.917,0.857 and 0.960,respectively.The AUC of serum miR-22-3p combined with CYR61 levels in the diagnosis of breast cancer was higher than that of either alone(Z=3.321 and 4.512,respectively,both P<0.05).Serum miR-22-3p levels were 0.45±0.12 and 0.71±0.24,and serum CYR61 levels were(162.94±29.78)and(118.53±25.49)μg/L,respectively,in patients with breast cancer recurrence and metastasis and those without metastasis.The serum miR-22-3p level in patients with breast cancer recurrence and metastasis was lower than that in patients without recurrence and metas-tasis,and the serum CYR61 level was higher than that in patients without recurrence and metastasis(t=5.216 and 7.365,respectively;both P<0.01).The AUC of serum miR-22-3p and CYR61 levels alone and combined in the diagnosis of breast cancer recurrence and metastasis were 0.838,0.831 and 0.932,respectively.The AUC of serum miR-22-3p and CYR61 levels combined in the diagnosis of breast cancer recurrence and metastasis was higher than that of either alone(Z=2.493 and 2.196,respectively;both P<0.05).Pearson correlation analysis showed that serum miR-22-3p level was nega-tively correlated with serum CYR61 level in breast cancer patients(r=-0.643,P<0.05).Conclusion Both the levels of serum miR-22-3p and CYR61 have certain value for the diagnosis of breast cancer and for the prediction on recurrence and metastasis,and the diagnostic value of them combined is higher.关键词
乳腺癌/微小RNA-22-3p/富含半胱氨酸蛋白61/复发转移Key words
breast carcinoma/microRNA-22-3p/cysteine-rich protein 61/diagnosis/recurrence and metastasis分类
医药卫生引用本文复制引用
喻珊珊,喻茂文,谭辉..血清miR-22-3p、CYR61水平对乳腺癌诊断及复发转移预测的临床价值[J].山东医药,2024,64(16):1-5,5.基金项目
国家重点基础研究发展计划(973计划)子课题(2015CB755402_108). （973计划）
